Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Catheter-based Atrial Septal Defect (ASD) Closure
Treatment for Congenital heart anomalies
Effectiveness
98%
Safety Score
60%
Clinical Trials
1
Participants
80K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Time to Effect
Immediate (shunt closure), recovery over days-weeks
Treatment Duration
Single procedure, long-term monitoring
Evidence Quality
HIGHConfidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50
Monitoring:$500
Side Effect Mgmt:$50
Total Annual:$600
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$30,000/QALY
QALYs Gained
12
Outcome-Based Costs
Cost per Responder
$612.24
Cost per Remission
$631.58
Comparison vs Surgical ASD Closure
Cost Difference
$-20,000/year
Less expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Catheter-based Atrial Septal Defect (ASD) Closure Outcomes
for Congenital heart anomalies
Efficacy Outcomes
Overall Effectiveness
+98%
Response Rate
+98%
Remission Rate
+95%
Common Side Effects
Device embolization/malposition
+1%
Perforation/tamponade
+0.5%
Arrhythmias (transient)
+5%
Groin hematoma/vascular injury
+5%
Residual shunt
+2%
Device erosion
+0.1%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
1 completed trial for Catheter-based Atrial Septal Defect (ASD) Closure in Congenital heart anomalies
Feasibility Study on the VERAFEYE System
NCT05931835COMPLETEDNA
18 participants
INTERVENTIONAL
Dublin, Ireland
Started: Jan 9, 2025